Cargando…
Advancing theranostics with tumor-targeting peptides for precision otolaryngology
Worldwide, about 600,000 head and neck squamous cell carcinoma (HNSCC) are detected annually, many of which involve high risk human papilloma virus (HPV). Surgery is the primary and desired first treatment option. Following surgery, the existence of cancer cells at the surgical margin is strongly as...
Autores principales: | Wright, Chadwick L., Pan, Quintin, Knopp, Michael V., Tweedle, Michael F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
KeAi Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698525/ https://www.ncbi.nlm.nih.gov/pubmed/29204554 http://dx.doi.org/10.1016/j.wjorl.2016.05.006 |
Ejemplares similares
-
Theranostic Imaging of Yttrium-90
por: Wright, Chadwick L., et al.
Publicado: (2015) -
Circulating tumor cells in head and neck cancer: A review
por: McMullen, Kyle P., et al.
Publicado: (2016) -
Theranostic role of radiolabelled RGD peptide in the treatment of radioiodine-resistant thyroid cancer: A novel agent
por: Vatsa, Rakhee, et al.
Publicado: (2020) -
Novel Peptide NIRF Optical Surgical Navigation Agents for HNSCC
por: Ding, Haiming, et al.
Publicado: (2019) -
The Otolaryngology Residency Program Preference Signaling Experience
por: Pletcher, Steven D., et al.
Publicado: (2021)